{"id":582713,"date":"2026-05-20T00:00:00","date_gmt":"2026-05-20T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0042-2026-biopharma-ovarian-cancer-unmet-need-unmet-need-recurrent-platinum-resistant-ovarian-cancer-us-eu\/"},"modified":"2026-05-20T00:00:00","modified_gmt":"2026-05-20T00:00:00","slug":"unneon0042-2026-biopharma-ovarian-cancer-unmet-need-unmet-need-recurrent-platinum-resistant-ovarian-cancer-us-eu","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0042-2026-biopharma-ovarian-cancer-unmet-need-unmet-need-recurrent-platinum-resistant-ovarian-cancer-us-eu\/","title":{"rendered":"Ovarian Cancer &#8211; Unmet Need &#8211; Unmet Need &#8211; Recurrent Platinum-Resistant Ovarian Cancer (US EU)"},"content":{"rendered":"<p>The treatment landscape for advanced platinumresistant ovarian cancer remains highly challenging, as conventional singleagent chemotherapies provide limited and shortlived benefit. Unlike the progress seen in platinumsensitive disease, effective and durable options for platinumresistant patients are scarce. A key recent advance has been the introduction of mirvetuximab soravtansine for <abbr title=\"folate receptor alpha\">FR\u03b1<\/abbr>high tumors, marking the first meaningful targeted therapy in this setting and highlighting the potential for biomarkerdriven approaches. However, for the broader population without high <abbr title=\"folate receptor alpha\">FR\u03b1<\/abbr> expression, therapeutic choices remain few, and response rates remain low, reinforcing the substantial unmet need that continues to define platinumresistant ovarian cancer.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"BulletListStyle1 SCXW92580611 BCX0 round-bullets\">\n<li>Which attributes most influence physicians\u2019 prescribing decisions in the treatment of platinum-resistant ovarian cancer?<\/li>\n<li>How do medical oncologists rate the performance of therapies, such as mirvetuximab soravtansine, on key treatment drivers and goals for this patient population?<\/li>\n<li>What are the prevailing areas of unmet need in the treatment of platinum-resistant ovarian cancer?<\/li>\n<li>What trade-offs across different clinical attributes and prices are acceptable to surveyed medical oncologists for a hypothetical treatment of platinum-resistant ovarian cancer?<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States, United Kingdom, France, Germany<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60 U.S. and 31\u00a0European medical oncologists fielded in March 2026<\/p>\n<p><strong>Key drugs: <\/strong>Mirvetuximab soravtansine<\/p>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><a>Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:<\/a><\/p>\n<ul class=\"round-bullets\">\n<li>Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians\u2019 weightings and analysis of stated vs. derived importance.<\/li>\n<li>Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.<\/li>\n<li>Analyze market scenarios for different target product profiles using the <abbr title=\"Target Product Profile\">TPP<\/abbr> Simulator.<\/li>\n<\/ul>\n<p><strong>KEY FEATURE<\/strong><\/p>\n<p>Target Product Profile (<abbr title=\"Target Product Profile\">TPP<\/abbr>) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven <abbr title=\"Target Product Profile\">TPP<\/abbr>s across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.<\/p>\n","protected":false},"template":"","class_list":["post-582713","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-ovarian-cancer","biopharma-therapy-areas-solid-tumors","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/582713","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":0,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/582713\/revisions"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=582713"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}